Amedisys
- Home ›
- US ›
- Healthcare
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. The last earnings update was 47 days ago. More info.
Add to Portfolio Compare Print
AMED Share Price and Events
7 Day Returns
1 Year Returns
AMED Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Amedisys (AMED) | 1.8% | 10.3% | -5.5% | 40.5% | 143.6% | 777.6% |
| US Healthcare | 0.1% | 2.8% | -2.8% | -3.8% | 22.9% | 61.3% |
| US Market | 0.3% | 0.4% | 0.6% | 0.7% | 37.2% | 37.4% |
1 Year Return vs Industry and Market
- AMED outperformed the Healthcare industry which returned -3.8% over the past year.
- AMED outperformed the Market in United States of America which returned 0.7% over the past year.
AMED Value
Is Amedisys undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Amedisys
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Amedisys.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 12 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 7.5% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Healthcare Unlevered Beta | Simply Wall St/ S&P Global | 0.64 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.638 (1 + (1- 21%) (10.21%)) |
0.792 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.8 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%) |
7.5% |
Discounted Cash Flow Calculation for NasdaqGS:AMED using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Amedisys is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 7.5%) |
|
|---|---|---|---|
| 2019 | 158.73 | Analyst x2 | 147.66 |
| 2020 | 182.57 | Analyst x3 | 157.99 |
| 2021 | 200.99 | Est @ 10.09% | 161.80 |
| 2022 | 216.84 | Est @ 7.88% | 162.38 |
| 2023 | 230.58 | Est @ 6.34% | 160.63 |
| 2024 | 242.70 | Est @ 5.26% | 157.28 |
| 2025 | 253.61 | Est @ 4.5% | 152.89 |
| 2026 | 263.68 | Est @ 3.97% | 147.87 |
| 2027 | 273.16 | Est @ 3.6% | 142.50 |
| 2028 | 282.27 | Est @ 3.34% | 136.98 |
| Present value of next 10 years cash flows | $1,527.97 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $282.27 × (1 + 2.73%) ÷ (7.5% – 2.73%) |
$6,081.75 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $6,081.75 ÷ (1 + 7.5%)10 |
$2,951.38 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $1,527.97 + $2,951.38 |
$4,479.35 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $4,479.35 / 32.04 |
$139.78 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $139.78 |
| Current discount | Discount to share price of
$119.53
= -1 x ($119.53 - $139.78) / $139.78 |
14.5% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Amedisys's share price is below the future cash flow value, but not at a moderate discount (< 20%).
- Amedisys's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Amedisys's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Amedisys's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $3.82 |
| NasdaqGS:AMED Share Price ** | NasdaqGS (2019-06-17) in USD | $119.53 |
| United States of America Healthcare Industry PE Ratio | Median Figure of 57 Publicly-Listed Healthcare Companies | 22.53x |
| United States of America Market PE Ratio | Median Figure of 3,093 Publicly-Listed Companies | 17.68x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Amedisys.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:AMED Share Price ÷ EPS (both in USD) = 119.53 ÷ 3.82 |
31.26x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Amedisys is overvalued based on earnings compared to the US Healthcare industry average.
- Amedisys is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does
Amedisys's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 31.26x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts |
15.9%per year |
| United States of America Healthcare Industry PEG Ratio | Median Figure of 43 Publicly-Listed Healthcare Companies | 1.68x |
| United States of America Market PEG Ratio | Median Figure of 2,125 Publicly-Listed Companies | 1.52x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 31.26x ÷ 15.9% |
1.97x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Amedisys is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Amedisys's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $16.24 |
| NasdaqGS:AMED Share Price * | NasdaqGS (2019-06-17) in USD | $119.53 |
| United States of America Healthcare Industry PB Ratio | Median Figure of 93 Publicly-Listed Healthcare Companies | 2.31x |
| United States of America Market PB Ratio | Median Figure of 5,245 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:AMED Share Price ÷ Book Value per Share (both in USD) = 119.53 ÷ 16.24 |
7.36x |
* Primary Listing of Amedisys.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Amedisys is overvalued based on assets compared to the US Healthcare industry average.
Value checks
We assess Amedisys's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check) Amedisys has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
AMED Future Performance
How is Amedisys expected to perform in the next 1 to 3 years based on estimates from 12 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Amedisys's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Amedisys's earnings growth is expected to exceed the United States of America market average.
- Amedisys's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:AMED Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts | 15.9% |
| NasdaqGS:AMED Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts | 7.9% |
| United States of America Healthcare Industry Earnings Growth Rate | Market Cap Weighted Average | 12.2% |
| United States of America Healthcare Industry Revenue Growth Rate | Market Cap Weighted Average | 6.2% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.8% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 12 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | 2,277 | 189 | 1 | |
| 2020-12-31 | 2,103 | 192 | 153 | 12 |
| 2019-12-31 | 1,967 | 133 | 130 | 12 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 1,731 | 203 | 123 |
| 2018-12-31 | 1,663 | 223 | 119 |
| 2018-09-30 | 1,624 | 192 | 88 |
| 2018-06-30 | 1,580 | 133 | 71 |
| 2018-03-31 | 1,546 | 119 | 42 |
| 2017-12-31 | 1,511 | 106 | 30 |
| 2017-09-30 | 1,474 | 102 | 43 |
| 2017-06-30 | 1,456 | 99 | 40 |
| 2017-03-31 | 1,438 | 77 | 46 |
| 2016-12-31 | 1,419 | 62 | 37 |
| 2016-09-30 | 1,391 | 54 | 41 |
| 2016-06-30 | 1,358 | 78 | 38 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 12 Analyst Estimates (S&P Global) | See Below |
All data from Amedisys Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | 5.57 | 5.57 | 5.57 | 1.00 |
| 2020-12-31 | 4.56 | 4.75 | 4.39 | 8.00 |
| 2019-12-31 | 3.93 | 3.94 | 3.91 | 8.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | 3.82 |
| 2018-12-31 | 3.64 |
| 2018-09-30 | 2.65 |
| 2018-06-30 | 2.11 |
| 2018-03-31 | 1.25 |
| 2017-12-31 | 0.90 |
| 2017-09-30 | 1.28 |
| 2017-06-30 | 1.19 |
| 2017-03-31 | 1.39 |
| 2016-12-31 | 1.12 |
| 2016-09-30 | 1.24 |
| 2016-06-30 | 1.16 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Amedisys's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Amedisys has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
AMED Past Performance
How has Amedisys performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Amedisys has delivered over 20% year on year earnings growth in the past 5 years.
- Amedisys's 1-year earnings growth exceeds its 5-year average (191.7% vs 67.9%)
- Amedisys's earnings growth has exceeded the US Healthcare industry average in the past year (191.7% vs 2.2%).
Earnings and Revenue History
All data from Amedisys Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 1,730.66 | 123.49 | 524.80 | |
| 2018-12-31 | 1,662.58 | 119.35 | 501.31 | |
| 2018-09-30 | 1,623.51 | 88.04 | 492.06 | |
| 2018-06-30 | 1,579.88 | 71.22 | 484.39 | |
| 2018-03-31 | 1,545.87 | 42.33 | 482.22 | |
| 2017-12-31 | 1,511.27 | 30.30 | 479.61 | |
| 2017-09-30 | 1,473.75 | 43.07 | 481.39 | |
| 2017-06-30 | 1,456.17 | 39.94 | 488.94 | |
| 2017-03-31 | 1,437.72 | 46.18 | 494.68 | |
| 2016-12-31 | 1,419.26 | 37.26 | 503.43 | |
| 2016-09-30 | 1,391.18 | 41.26 | 498.85 | |
| 2016-06-30 | 1,357.87 | 38.26 | 487.03 | |
| 2016-03-31 | 1,312.77 | 38.20 | 475.93 | |
| 2015-12-31 | 1,266.49 | -3.02 | 452.44 | |
| 2015-09-30 | 1,230.36 | -6.80 | 437.34 | |
| 2015-06-30 | 1,203.64 | -6.80 | 427.01 | |
| 2015-03-31 | 1,193.01 | -9.88 | 419.45 | |
| 2014-12-31 | 1,188.26 | 12.99 | 432.74 | |
| 2014-09-30 | 1,190.76 | -4.31 | 441.12 | |
| 2014-06-30 | 1,192.00 | -103.09 | 454.71 | |
| 2014-03-31 | 1,202.56 | -108.65 | 464.33 | |
| 2013-12-31 | 1,233.46 | -93.11 | 470.77 | |
| 2013-09-30 | 1,278.35 | -190.88 | 486.11 | |
| 2013-06-30 | 1,339.87 | -90.18 | 497.00 | |
| 2013-03-31 | 1,394.27 | -83.67 | 512.04 | |
| 2012-12-31 | 1,419.83 | -80.26 | 516.67 | |
| 2012-09-30 | 1,441.38 | 33.11 | 520.16 | |
| 2012-06-30 | 1,448.46 | -399.49 | 528.36 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Amedisys has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Amedisys used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.
- Amedisys has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Amedisys's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Amedisys has a total score of 6/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
AMED Health
How is Amedisys's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Amedisys's finances.
The net worth of a company is the difference between its assets and liabilities.
- Amedisys's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Amedisys's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Amedisys Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 521.20 | 391.13 | 10.55 |
| 2018-12-31 | 482.63 | 7.39 | 20.23 |
| 2018-09-30 | 445.50 | 56.06 | 14.01 |
| 2018-06-30 | 409.06 | 124.61 | 25.90 |
| 2018-03-31 | 549.56 | 86.20 | 120.01 |
| 2017-12-31 | 516.43 | 88.84 | 86.36 |
| 2017-09-30 | 513.22 | 89.91 | 66.11 |
| 2017-06-30 | 493.06 | 91.29 | 59.16 |
| 2017-03-31 | 482.95 | 92.36 | 48.33 |
| 2016-12-31 | 461.14 | 93.03 | 30.20 |
| 2016-09-30 | 446.38 | 94.09 | 8.92 |
| 2016-06-30 | 427.83 | 94.50 | 9.97 |
| 2016-03-31 | 410.78 | 110.57 | 7.82 |
| 2015-12-31 | 410.44 | 96.63 | 27.50 |
| 2015-09-30 | 393.97 | 100.00 | 57.05 |
| 2015-06-30 | 380.05 | 95.52 | 33.20 |
| 2015-03-31 | 367.44 | 98.44 | 3.13 |
| 2014-12-31 | 397.76 | 116.37 | 8.03 |
| 2014-09-30 | 383.10 | 114.30 | 5.54 |
| 2014-06-30 | 371.04 | 144.28 | 11.23 |
| 2014-03-31 | 362.92 | 42.95 | 2.84 |
| 2013-12-31 | 372.48 | 46.90 | 17.30 |
| 2013-09-30 | 377.79 | 70.86 | 43.63 |
| 2013-06-30 | 465.03 | 74.81 | 30.12 |
| 2013-03-31 | 461.78 | 78.76 | 7.02 |
| 2012-12-31 | 454.23 | 102.71 | 14.55 |
| 2012-09-30 | 571.98 | 122.16 | 39.11 |
| 2012-06-30 | 541.32 | 128.40 | 37.16 |
- Amedisys's level of debt (59.4%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (12.1% vs 59.4% today).
- Debt is well covered by operating cash flow (65.6%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 18.5x coverage).
Financial health checks
We assess Amedisys's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Amedisys has a total score of 2/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
AMED Dividends
What is Amedisys's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Amedisys
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Amedisys's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Amedisys's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 12 Analyst Estimates (S&P Global) | See Below |
| United States of America Healthcare Industry Average Dividend Yield | Market Cap Weighted Average of 21 Stocks | 1.6% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2011 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-12-31 | 0.00 | 1.00 |
| 2020-12-31 | 0.00 | 2.00 |
| 2019-12-31 | 0.00 | 2.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Amedisys has not reported any payouts.
- Unable to verify if Amedisys's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Amedisys's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Amedisys afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Amedisys has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
AMED Management
CEO
| COMPENSATION | $4,866,439 |
| AGE | 57 |
| TENURE AS CEO | 4.5 years |
CEO Bio
Mr. Paul Berthold Kusserow has been the Chief Executive Officer and President of Amedisys, Inc. since December 16, 2014. He serves as Chairman of the Advisory Board of Care Innovations. He has been the Chairman of the Board of Availity, LLC. since May 2013. He serves as member of the advisory board of Interpreta. He has been a Director of Community Care Health Network, Inc. since May 30, 2017. He has been a Director of Amedisys, Inc. since December 16, 2014. He serves as Director of Picwell Inc., New Century Health, Inc. and AxelaCare Health Solutions, LLC. He serves as a Director of IdealHire Technologies, Inc. Mr. Kusserow served as the President, Development of Alignment Healthcare, Inc. from June 2014 to December 2014. He served as the Chief Strategy, Innovations and Corporate Development Officer and Senior Vice President at Humana Inc. from January 2008 through December 2013. He served as the Chief Strategy Officer and Senior Vice President at Humana Venture Capital. He served as Managing Director and Chief Investment Officer at Ziegler HealthVest Fund at Contemporary Healthcare Capital, LLC. He served as a Managing Partner at Roaring Mountain, LLC and as an Entrepreneur-In-Residence at DW Healthcare Partners. He was the Managing Director of Private Equity at B.C. Ziegler and Company, Inc. He served as Executive-In-Residence of The Advisory Board Company. Previously, he co-founded San Ysidro Capital Partners LLC and served as its Managing Director from 2004 to 2007. From 1997 to 2004, he served as Tenet Healthcare Corporation's Senior Vice President of Corporate Strategy and Ventures, where he managed its venture investments and founded Tenet Ventures. He started his career as a Consultant with McKinsey & Company, Inc., where he specialized in marketing and organizational redesign. He has deep experience, especially in growing companies and corporate development. He previously served as the chairman of the board of directors of Availity Inc. and Healthsense, Inc. He served as Vice Chairman at Alignment Healthcare, Inc. since June 2014. He served as an Independent Director of Connecture, Inc. from October 2014 to April 25, 2018. He served as a Director of Actors Theatre of Louisville, Inc. He served as the Head of Planning and Marketing at the Colonial Williamsburg Foundation, where he was responsible for strategic planning, new business development and marketing. Mr. Kusserow also served senior executive positions in marketing, strategy and new business development at the National Geographic Society and the Reader's Digest Association. He was a Philip B. Brown Scholar, a Trench Prize recipient, an Olin Fellow and a Fellow at the Center for the Humanities at Wesleyan University. He received an M.A. degree, with honors, in English literature from the Oxford University. Mr. Kusserow graduated in BA in religious studies from the Wesleyan University.
CEO Compensation
- Paul's compensation has been consistent with company performance over the past year, both up more than 20%.
- Paul's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Amedisys management team in years:
- The tenure for the Amedisys management team is about average.
Management Team
Paul Kusserow
President
$5M
57
4.5 yrs
Scott Ginn
Chief Financial Officer
$1M
49
1.7 yrs
Chris Gerard
Chief Operating Officer
$1M
51
2.4 yrs
Dave Kemmerly
Senior VP of Government Affairs & General Counsel
$1M
55
3.7 yrs
Sharon Brunecz
Chief Human Resources Officer
$2M
51
1.1 yrs
Pete Hartley
CTO & Senior VP of Business Operations Systems
Michael North
Chief Information Officer
$1M
53
2.6 yrs
David Pearce
SVP & Chief Compliance Officer
57
2.9 yrs
Kendra Kimmons
Vice President of Marketing & Communications
John Nugent
Chief Acquisitions Officer
Board of Directors Tenure
Average tenure and age of the Amedisys board of directors in years:
- The tenure for the Amedisys board of directors is about average.
Board of Directors
Don Washburn
Non-Executive Chairman
$209K
74
4.8 yrs
Paul Kusserow
President
$5M
57
4.5 yrs
Jake Netterville
Director
$134K
80
22.4 yrs
Linda J. Keller
Director
$121K
69
6.3 yrs
Julie Klapstein
Director
$122K
63
3.2 yrs
Rich Lechleiter
Director
$125K
60
3.2 yrs
Nat Zilkha
Director
$114K
42
5.3 yrs
Bruce Perkins
Director
$122K
62
4.2 yrs
Jeff Rideout
Director
$105K
56
3.2 yrs
Who owns this company?
Recent Insider Trading
- Amedisys insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 13. Jun 19 | Sell | Scott Ginn | Individual | 10. Jun 19 | 10. Jun 19 | -4,872 | $118.50 | $-577,332 | ||
| 07. Jun 19 | Sell | Michael North | Individual | 05. Jun 19 | 05. Jun 19 | -5,248 | $115.01 | $-603,572 | ||
| 07. Jun 19 | Sell | David Kemmerly | Individual | 06. Jun 19 | 06. Jun 19 | -4,420 | $113.40 | $-501,228 | ||
| 18. May 19 | Buy | Bruce Perkins | Individual | 15. May 19 | 15. May 19 | 2,500 | $111.84 | $279,597 | ||
| 13. Mar 19 | Sell | David Pearce | Individual | 12. Mar 19 | 12. Mar 19 | -4,370 | $120.01 | $-524,444 | ||
| 13. Mar 19 | Sell | Christopher Gerard | Individual | 11. Mar 19 | 11. Mar 19 | -2,500 | $118.96 | $-297,400 | ||
| 07. Mar 19 | Sell | Jeffrey Rideout | Individual | 04. Mar 19 | 04. Mar 19 | -1,411 | $122.69 | $-171,549 | ||
| 10. Jan 19 | Sell | Linda J. Keller | Individual | 09. Nov 18 | 09. Nov 18 | -5,256 | $120.00 | $-630,720 | ||
| 20. Nov 18 | Sell | Jake Netterville | Individual | 15. Nov 18 | 16. Nov 18 | -3,394 | $126.64 | $-416,984 | ||
| 15. Nov 18 | Sell | Scott Ginn | Individual | 12. Nov 18 | 12. Nov 18 | -2,015 | $119.01 | $-238,566 | ||
Management checks
We assess Amedisys's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Amedisys has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
AMED News
Simply Wall St News
A Close Look At Amedisys, Inc.’s (NASDAQ:AMED) 18% ROCE
The formula for calculating the return on capital employed is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) Or for Amedisys: 0.18 = US$163m ÷ (US$1.2b - US$297m) (Based on the trailing twelve months to March 2019.) So, Amedisys has an ROCE of 18%. … Amedisys's Current Liabilities And Their Impact On Its ROCE Current liabilities include invoices, such as supplier payments, short-term debt, or a tax bill, that need to be paid within 12 months. … The ROCE equation subtracts current liabilities from capital employed, so a company with a lot of current liabilities appears to have less capital employed, and a higher ROCE than otherwise.
Simply Wall St - – Full articleIs It Too Late To Consider Buying Amedisys, Inc. (NASDAQ:AMED)?
And if you believe the company’s true value is $134.74, then there isn’t much room for the share price grow beyond what it’s currently trading. … AMED’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. … Will you have enough confidence to invest in the company should the price drop below its fair value?
Simply Wall St - – Full articleWhat You Should Know About Amedisys, Inc.'s (NASDAQ:AMED) Financial Strength
Does AMED Produce Much Cash Relative To Its Debt? … Additionally, AMED has produced US$203m in operating cash flow over the same time period, leading to an operating cash to total debt ratio of 52%, meaning that AMED’s operating cash is sufficient to cover its debt. … Looking at AMED’s US$297m in current liabilities, it seems that the business may not have an easy time meeting these commitments with a current assets level of US$272m, leading to a current ratio of 0.91x.
Simply Wall St - – Full articleHere's Why I Think Amedisys (NASDAQ:AMED) Might Deserve Your Attention Today
So it is good to see that Amedisys insiders have a significant amount of capital invested in the stock. … Although Amedisys certainly looks good to me, I would like it more if insiders were buying up shares. … If you like to see insider buying, too, then this free list of growing companies that insiders are buying, could be exactly what you're looking for.
Simply Wall St - – Full articleInvestors Who Bought Amedisys (NASDAQ:AMED) Shares Five Years Ago Are Now Up 676%
There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … During the five years of share price growth, Amedisys moved from a loss to profitability. … This EPS growth is higher than the 33% average annual increase in the share price over the same three years.
Simply Wall St - – Full articleIs Amedisys, Inc.'s (NASDAQ:AMED) Stock Available For A Good Price After Accounting For Growth?
Looking at Amedisys, Inc.’s (NASDAQ:AMED) fundamentals some investors are wondering if its last closing price of $127.88 represents a good value for money for this high growth stock. … See our latest analysis for Amedisys? … According to the analysts covering the company, the following few years should bring about good growth prospects for Amedisys
Simply Wall St - – Full articleWhat Are Analysts Saying About Amedisys, Inc.'s (NASDAQ:AMED) Future?
After Amedisys, Inc.'s (NASDAQ:AMED) earnings announcement in December 2018,. … with earnings expected to grow by 12% in the upcoming year … the higher past 5-year average growth rate of 71%
Simply Wall St - – Full articleCalculating The Intrinsic Value Of Amedisys, Inc. (NASDAQ:AMED)
Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model? … We're using the 2-stage growth model, which simply means we take in account two stages of company's growth … In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate.
Simply Wall St - – Full articleBoasting A 25% Return On Equity, Is Amedisys, Inc. (NASDAQ:AMED) A Top Quality Stock?
This article is for those who would like to learn about Return On Equity (ROE). … Another way to think of that is that for every $1 worth of equity in the company, it was able to earn $0.25. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleAre Insiders Selling Amedisys, Inc. (NASDAQ:AMED) Stock?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So shareholders might well want to know whether insiders have been buying or selling shares in Amedisys, Inc. … Over the last year we saw more insider selling of Amedisys shares, than buying
Simply Wall St - – Full articleAMED Company Info
Description
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer’s, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2019, the company owned and operated 472 care centers in 38 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Details
| Name: | Amedisys, Inc. |
| AMED | |
| Exchange: | NasdaqGS |
| Founded: | 1982 |
| $3,830,320,681 | |
| 32,044,848 | |
| Website: | http://www.amedisys.com |
| Address: |
Amedisys, Inc. 3854 American Way, Suite A, Baton Rouge, Louisiana, 70816, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | AMED | Common Stock | Nasdaq Global Select | US | USD | 06. Jan 1994 | |
| DB | ADY | Common Stock | Deutsche Boerse AG | DE | EUR | 06. Jan 1994 | |
| BMV | AMED * | Common Stock | Bolsa Mexicana de Valores | MX | MXN | 06. Jan 1994 |
Number of employees
Current staff
Industry
| Health Care Services | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/17 23:31 |
| End of day share price update: | 2019/06/17 00:00 |
| Last estimates confirmation: | 2019/06/05 |
| Last earnings filing: | 2019/05/01 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
